Press releases

Genoskin raises $8.7M series Ato support drug development with ethical, human-based modelsFunding to accelerate global expansion and strengthen scientific leadership We are excited to announce that Genoskin, a leader in developing ex vivo human skin platforms for testing drugs and medical devices, has raised $8.7 million (€8M) in Series A funding. The investment will fuel the company’s global expansion, enhanceRead more

Research HighlightExplore our latest publication in Allergy: the story behind the idea and key findings.The landscape of vaccine research is undergoing an important transformation, thanks to the breakthroughs in mRNA vaccine technology. This innovation has catalyzed the development of vaccines that are not only highly effective but also rapidly deployable at a large scale. With the increasing number of researchRead more

PRESS RELEASE - Salem, MA, USA - October 3rd, 2023 Genoskin introduces ImmunoSafe: ISR Platform® with AUDACY - A revolutionary leap in non-clinical local toxicity assessment Salem, MA, October 3rd, 2023 - Genoskin, a biotechnology company at the forefront of accelerating drug development, proudly announces the enhancement of its ISR Platform® with the integration of AUDACY, a state-of-the-art bioinformatics-based analyticalRead more

PRESS RELEASE - Toulouse, France - June 8th, 2023 Introducing MANTIS®: A Breakthrough Analytic Pipeline for Unraveling the Complexity of Inflammatory Skin Conditions. Toulouse, France, June 8, 2023 - Genoskin is proud to announce the publication of a groundbreaking scientific article in Science Advances, introducing a new analytic pipeline called MANTIS® (Multiplexed Annotated Tissue Imaging System). The article, authored byRead more

PRESS RELEASE - Washington D.C. - April 3, 2023 Genoskin and PharmaJet announce strategic research partnership to advance precision vaccine delivery Washington D.C., April 3, 2023 - Genoskin, a leading Franco-American TechBio company specializing in bio-stabilized immunocompetent human skin platforms, and PharmaJet, an innovative provider of Precision Delivery Systems (PDS), announce a strategic research partnership during the World Vaccine Congress.Read more

PRESS RELEASE - Toulouse, France - May 2022 Dr. Florent Ginhoux joins Genoskin’s Scientific Advisory Board Genoskin is thrilled to welcome Dr. Florent Ginhoux, PhD, to its Scientific Advisory Board (SAB). After last year's nomination of world-renowned immunology expert, Dr. Nicolas Gaudenzio, as Genoskin’s CSO, Dr. Ginhoux will now bring his world-class expertise as Highly Cited Researcher in tissue-resident immuneRead more